Target: Nipah virus

Nipah virus is a deadly, bat-borne zoonotic virus. It has a high mortality rate (up to 75%) and was first found in Southeast Asia in 1998. Once infected, individuals experience a wide variety of symptoms ranging from fever and headaches to encephalitis and severe respiratory distress.

Glycoprotein G (gpG) on the surface of the virus binds to human ephrin B2 and B3 receptors on human cells, particularly in the nervous system.

Today, there are a few anti-gpG monoclonal antibodies that are making their way through human trials: m102.4, MBP1F5, and mAb92, but there’s still a need for developing more therapeutics against Nipah virus. We participated in the Adaptyv Bio Nipah Binder Competition, submitting ~160 scFv candidates using our 🦋peleke-1 antibody language models.

So, how’d we do?

One of our best candidates, sbio-nipahgpg-120 (in yellow), bound to glycoprotein G (in grey).

A horizontal bar graph showing various biochemical data with columns labeled HDACock Score, Total Energy, Van der Waals Energy, Electrostatic Energy, and Buried Surface Area, with sample labels such as sbio-nipahhpg-120 and sbio-nipahhpg-128.

Various binding affinity metrics of our generated anti-gpG antibody candidates.

✉ Want to Learn More?

🦋 Made with our peleke-1 models

A grid of twelve molecular structure diagrams showing proteins in yellow and gray, with some blue elements, labeled with various 'sbio-nipahgp' numbers.

Top 10 Candidates (by lowest HADDOCK score and iPDE < 10)